Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2007, Vol. 12 ›› Issue (10): 1130-1137.
• Full article • Previous Articles Next Articles
LIU Jie, LIU Zhao-qian, LIU Ying-zi, TAN Zhi-rong, HU Dong-li, LI Zhi, WANG Dan, ZHANG Wei, ZHOU Hong-hao
Online:
2007-10-26
Published:
2020-11-04
Contact:
ZHOU Hong-hao, male, MD, professor and director, academician of Chinese Academy of Engineering.Tel:86-731-4805380 E-mail:hhzhou @public.cs.hn.cn
LIU Jie, LIU Zhao-qian, LIU Ying-zi, TAN Zhi-rong, HU Dong-li, LI Zhi, WANG Dan, ZHANG Wei, ZHOU Hong-hao. Effects ofβ1-adrenergic receptor and CYP2D6 genetic polymorphism on metoprolol pharmacokinetics and pharmacodynamics in antihypertension therapy[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(10): 1130-1137.
1 Evans WE, Relling MV.Pharmacogenomics:translating functional genomics into rational therapeutics[J].Science, 1999; 286:487-491. 2 EvansWE, Johnson JA.Pharmacogenomics:The inherited basis for interindividual differences in drug response[J].Ann Rev Genomics Hum Genet, 2001;2:9-39. 3 McLeod HL, EvansWE.Pharmacogenomics:unlocking the human genome for better drug therapy[J].Ann Rev Pharmacol Toxicol, 2001;41:101-121. 4 Roses AD.Pharmacogenetics[J].Hum Mol Genet, 2001;10: 2261-2267. 5 Sachidananandam R, Weissman D, Schmidt SC, et al. The International SNP Map Working Group.A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms[J].Nature, 2001;409:928-933. 6 Relling MV, Hancock ML, Rivera GK, et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus[J].J Natl Cancer Inst, 1999;23:1983-1985. 7 Black AJ, McLeod HL, CapelL/hA, et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine[J].Ann Intern Med, 1998;129:716-718. 8 Evans WE, Hon YY, Bomgaars L, et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine[J]. J Clin Oncol, 2001;19:2293-2301. 9 Dishy V, Sofowora GG, Xie HG, et al. The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization[J].N Engl J Med, 2001;14:1030-1035. 10 Drazen JM, Yandava CN, Dube L, et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment[J].Nat Genet, 1999;22:168-170. 11 Amadio P Jr, Cummings DM, Amadio PB.β-blocker therapy for hypertension.Considerations in selecting the most appropriate agent[J].PostgradMed, 1987;82:152-159. 12 Venter CP, Joubert PH.Ethnic differences in response toβ1-adrenoceptor blockade by propranolol[J].J Cardiovasc Pharmacol, 1984;6:361-364. 13 Venter CP, Joubert PH, Strydom WJ.The relevance of ethnic differences in hemodynamic responses to the head-up tilt manoeuvre to clinical pharmacological investigations[J].J Cardiovasc Pharmacol, 1985;7:1009-1010. 14 Zhou HH, Koshakji RP, Silberstein DJ, et al. Racial differences in drug response:altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites[J].N Engl JMed, 1989;320:565-570. 15 Veterans Administration Cooperative Study Group.Antihypertensive agents[J].JAMA, 1982;248:2004-2011. 16 Materson BJ, Reda DJ, CushmanWC, et al. Single-drug therapy for hypertension in men.A comparison of six antihypertensive agents with placebo.The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents[J].N Engl J Med, 1993;328:914-921. 17 LennardMS, Silas JH, Freestone S, et al. Oxidation phenotypr:a major determinant of metoprolol metabolism and response[J].N Engl J Med, 1982, 307:1158-1160. 18 Daly AK.Pharmacogenetics of the cytochromes P450[J].Curr Top Med Chem, 2004;4:1733-1744. 19 Nakamura K, Ariyoshi N, Yokoi T, et al. CYP2D6.10 present in human liver microsomes shows low catalytic activity and thermal stability[J].Biochem Biophys Res Commun, 2002;293: 969-973. 20 Garcia-Barcelo M, Chow LY, Chiu HF, et al. Genetic analysis of the CYP2D6 locus in a Hong Kong Chinese population[J]. Clin Chem, 2000;46:18-23. 21 Kirchheiner J, Meineke I, Muller G, et al. Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of Eand Z-doxepin in healthy volunteers[J].Pharmacogenetics, 2002;12:571-580. 22 Ambrosioni E, Bacchelli S, Esposti DD, et al. Beta-blockade in hypertension and congestive heart failure[J].J Cardiovasc Pharmacol, 2001;38 Suppl 3:S25-S31. 23 Deroubaix X, Lins RL, Lens S, et al. Comparative bioavailability of a metoprolol controlled release formulation and a bisoprolol normal release tablet after single oral dose administration in healthy volunteers[J].Int J Clin Pharmacol Ther, 1996;34: 61-70. 24 Wuttke H, Rau T, Heide R, et al. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects [J].Clin Pharmacol Ther, 2002;72:429-437. 25 Turki J, Pak J, Green S, et al. Genetic polymorphisms of the β2-adrenergic receptor in nocturnal and non-nocturnal asthma. Evidence that Gly 16 correlates with the nocturnal phenotype [J].J Clin Invest, 1995;95:1635-1641. 26 Martinez FD, Graves PE, Baldini M, et al. Association between genetic polymorphisms of the β2-adrenoceptor and response to albuterol in children with and without a history of wheezing[J].J Clin Invest, 1997:100:3184-3188. 27 Reihsaus E, Innis M, MacIntyre N, et al. Mutations in the gene encoding for the β2 adrenergic receptor in normal and asthmatic subjects[J].Am J Respir Cell Mol Biol, 1993;8:334-339. 28 Bray MS, Krushkal J, Li L, et al. Positional genomic analysis identifies the beta (2)-adrenergic receptor gene as a susceptibility locus for human hypertension[J].Circulation, 2000; 101:2877-2882. 29 Arranz M, Collier D, Sodhi M, et al. Association between clozapine response and allelic variation in 5-HT2A receptor gene [J].Lancet, 1995;346:281-282. 30 Arranz MJ, Munro J, Bolonna A, et al. Pharmacogenetic prediction of clozapine response[J].Lancet, 2000;355:1615-1616. |
[1] | LIU Lu, SHI Yufei, HE Qingfeng, XU Fengyan, WANG Kun, CAI Weimin, XIANG Xiaoqiang. Application of population modeling analysis to evaluate the impact of gene polymorphism on drug PK/PD [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1275-1282. |
[2] | LIN Rongfang, ZHENG Weiwei, LIU Yiwei, LIN Cuihong, WANG Changlian, HUANG Pinfang. Correlation of infliximab related genetic polymorphism, serum trough concentration and efficacy in patients with Crohn's disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1000-1006. |
[3] | TANG Mufei, SHEN Yunzhu, ZHANG Baoguo. Influence of CYP2D6 gene polymorphism on the effect of tropisetron in preventing chemotherapy induced nausea and vomiting [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 817-822. |
[4] | LI Ling, ZHAO Huijia, CHEN Binyao, LIU Xiaohong, SUN Gongpeng, HAO Zhuowen, FAN Zhipeng, YUE Jiang, WU Jianguo, YE Qifa. Relevance of CYP2R1 genetic polymorphism and individual therapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 1053-1059. |
[5] | WANG Ente, ZHANG Xiaodan, ZHOU Shuang, ZHAO Xia, ZHOU Ying, CUI Yimin. Effects of genetic polymorphisms on metabolic kinetics, pharmacodynamics and adverse reactions of amitriptyline [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(2): 235-240. |
[6] | CHEN Binyao, LI Ling, ZHAO Huijia, LIU Xiaohong, QI Zhenhua, SUN Gongpeng, HAO Zhuowen, FAN Zhipeng, DONG Li, YUE Jiang, YE Qifa. Relevance of CYP1B1 genetic polymorphism and individual therapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(11): 1309-1316. |
[7] | ZHOU Yuan, LU Xueling, ZHAO Jun, ZHANG Li, YANG Huanjie,WANG Ning. Polymorphism distribution of rs316019 of SLC22A2 in the Uygur population of Xinjiang [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(3): 287-293. |
[8] | LIN Xiuxian, CHEN Dan, ZHAO Qing, CHEN Yao. Genetic research on the incidence of alcoholic liver disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(11): 1309-1314. |
[9] | WANG Ying-ying, CHENG Guang-hua, PU Zhi-chen, GE Jun-liang, XIE Yan, CHEN Xiao-lei. Association between CYP2D6*10/CYP2C19*2 genotype polymorphism and survival of breast cancer patients receiving tamoxifen treatment [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(5): 552-556. |
[10] | HU Jing, ZHU Jun-rong, YU Feng. Efficacy and safety of warfarin dosage algorithms in clinical application:A Meta-analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(3): 296-303. |
[11] | MA Xiao-qin, XIN Hua-wen, LI Yuan-qi, HUANG Hui, ZHAO Li, YU Ai-rong, LI Wei-liang, WU Xiao-chun. Association of HGPRT activity and gene polymorphism with adverse reactions caused by azathioprine in kidney transplant recipients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(2): 182-187. |
[12] | WU Ji-chu, OUYANG Ze-wei, LUO Can-xiang. Effect of ABCG2 genetic polymorphism on atorvastatin modifying serum lipids [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(8): 882-884. |
[13] | OUYANG Cang-hong, XIE Juan. Study on the relationship between the MDR1 and CYP3A genetic polymorphisms and serum digoxin concentration in 111 patients with chronic heart failure [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(3): 291-296. |
[14] | FENG Jing, WU Yue, RONG Pei-pei, SHEN Bing-zheng, ZHOU Ding-shan, SHI Cai, SONG Jin-chun. Progress on effects of pharmacogenetics of inosine triphosphate pyrophosphatase on improving the individualized thiopurine therapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(12): 1435-1440. |
[15] | ZHU Hong-xia, WANG Xue-feng, XU Qian. Clinical comparative study on nifedipine sustained release tablets combined separately with enalapril maleate tablets and metoprolol tartrate tablets in treating high-risk hypertensive patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(10): 1167-1170. |
Viewed | ||||||||||||||||||||||||||||||||||||||||||||||||||
Full text 447
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Abstract 126
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||